Andrew D. Zelenetz
A5061964017- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Lung Cancer Treatments and Mutations
- CNS Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Ovarian cancer diagnosis and treatment
- Immunodeficiency and Autoimmune Disorders
- Monoclonal and Polyclonal Antibodies Research
- T-cell and Retrovirus Studies
- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- Cutaneous lymphoproliferative disorders research
- Medical Imaging Techniques and Applications
- Multiple and Secondary Primary Cancers
- Radiopharmaceutical Chemistry and Applications
- Cancer Treatment and Pharmacology
- Immune Cell Function and Interaction
- Protein Degradation and Inhibitors
- Hepatitis B Virus Studies
- Histone Deacetylase Inhibitors Research
- Acute Myeloid Leukemia Research
- Sarcoma Diagnosis and Treatment
Memorial Sloan Kettering Cancer Center
2016-2025
Kettering University
2000-2024
Cornell University
2015-2024
Weill Cornell Medicine
2017-2022
BeiGene (China)
2017-2020
Amgen (United States)
2017-2020
Janssen (Belgium)
2017-2020
Roche (Switzerland)
2010-2020
Gilead Sciences (Spain)
2020
Adaptive Biotechnologies (United States)
2020
Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B-cell–like [ABC], germinal-center [GCB], unclassified) according to cell origin that associated with a differential response chemotherapy targeted agents. We sought extend these findings by identifying genetic subtypes based on shared genomic abnormalities uncover therapeutic vulnerabilities tumor genetics.
Patients with relapsed chronic lymphocytic leukemia (CLL) who have clinically significant coexisting medical conditions are less able to undergo standard chemotherapy. Effective therapies acceptable side-effect profiles needed for this patient population. In multicenter, randomized, double-blind, placebo-controlled, phase 3 study, we assessed the efficacy and safety of idelalisib, an oral inhibitor delta isoform phosphatidylinositol 3-kinase, in combination rituximab versus plus placebo. We...
Since the publication of Revised European-American Classification Lymphoid Neoplasms in 1994, subsequent updates classification lymphoid neoplasms have been generated through iterative international efforts to achieve broad consensus among hematopathologists, geneticists, molecular scientists, and clinicians. Significant progress has recently made characterization malignancies immune system, with many new insights provided by genomic studies. They led this proposal. We followed same process...
Twenty percent of patients with follicular lymphoma (FL) experience progression disease (POD) within 2 years initial chemoimmunotherapy. We analyzed data from the National LymphoCare Study to identify whether prognostic FL factors are associated early POD and at high risk for death.In total, 588 stage 4 received first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP). Two groups were defined: or less after diagnosis those without years, reference group. An...
PURPOSE: To evaluate the efficacy and safety of tositumomab iodine I 131 (Bexxar; Corixa Corp, Seattle, WA, GlaxoSmithKline, Philadelphia, PA) in patients with chemotherapy-refractory low-grade or transformed non-Hodgkin’s lymphoma (NHL) to compare its patients’ last qualifying chemotherapy (LQC) regimens. PATIENTS AND METHODS: Sixty who had been treated at least two protocol-specified regimens not responded progressed within 6 months after their LQC were a single course tositumomab....
To determine the antitumor activity of novel proteasome inhibitor bortezomib in patients with indolent and mantle-cell lymphoma (MCL).Patients MCL were eligible. Bortezomib was given at a dose 1.5 mg/m2 on days 1, 4, 8, 11. Patients required to have received no more than three prior chemotherapy regimens, least 1 month since treatment, 3 months from rituximab, 7 corticosteroids; absolute neutrophil count 1,500/microL (500/microL if documented bone marrow involvement); platelet...
Part 1 Lymphomagenesis: Lymphocyte differentiation Adult T-cell leukaemia/Lymphoma - a model of retrovirus-induced lymphomagenesis Burkitt's lymphoma and Epstein-Barr virus-associated lymphoid malignancies models for T(14 18) translocation. 2 Methods: Histological immunohistochemical methods Genotype. 3 Nodal Non-Hodgkin's Lymphomas: The normal lymph node structure function classification Staging NHLs Analytical study the different subtypes clinical, histological aspects in childhood...
To document the toxicity and activity of histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with pretreated hematologic malignancies.Two formulations SAHA (intravenous [IV] oral) have been assessed two consecutive phase I trials. In both trials, dose escalation was performed parallel independently solid tumors malignancies. Eligible were required to adequate hepatic renal function, an absolute neutrophil count > or = 500/microL a platelet more than 25,000/mL....
Alliance/CALGB 50303 (NCT00118209), an intergroup, phase III study, compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) with standard rituximab, prednisone (R-CHOP) as frontline therapy for diffuse large B-cell lymphoma.Patients received six cycles of DA-EPOCH-R or R-CHOP. The primary objective was progression-free survival (PFS); secondary clinical objectives included response rate, overall (OS), safety.Between 2005 2013, 524...
PURPOSE In studies of diffuse large B-cell lymphoma, positron emission tomography with [(18)F]fluorodeoxyglucose (FDG-PET) performed after two to four cycles chemotherapy has demonstrated prognostic significance. However, some patients treated immunochemotherapy experience a favorable long-term outcome despite positive interim FDG-PET scan. To clarify the significance scans, we prospectively studied FDG-positive disease within risk-adapted sequential program. PATIENTS AND METHODS From March...
Purpose Optimal therapy of follicular lymphoma (FL) is not defined. We analyzed a large prospective cohort study to identify current demographics and patterns care FL in the United States. Patients Methods The National LymphoCare Study multicenter, longitudinal, observational designed collect information on treatment regimens outcomes for patients with newly diagnosed were enrolled between 2004 2007. There no study-specific prescribed regimen or intervention. Results Two thousand seven...